8-K: Coya Therapeutics Announces Positive Phase 2 Trial Results for Low-Dose IL-2 in Alzheimer's Disease

Coya Therapeutics' Phase 2 trial of low-dose Interleukin-2 (LD IL-2) in Alzheimer's patients met its primary and secondary endpoints, showing safety and an increase in regulatory T cells.

Summary

• Coya Therapeutics announced positive results from a Phase 2 clinical trial of low-dose Interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer's Disease.
• The study, which was placebo-controlled and double-blind, evaluated two different dosing regimens of subcutaneous LD IL-2.
• The primary endpoint of the study was safety and tolerability, which was met with no serious adverse events reported.
• The secondary endpoint, which was the change in regulatory T cell (Treg) populations, was also met, with a significant increase in Tregs observed in both dosing groups compared to placebo.
• Exploratory endpoints included changes in cerebrospinal fluid (CSF) biomarkers and cognitive status.
• The LD IL-2 administered every four weeks (q4wks) group showed a significant improvement in CSF soluble A42 levels, a marker of amyloid pathology, and a trend towards cognitive stabilization.
• The LD IL-2 administered every two weeks (q2wks) group did not show the same benefits in exploratory endpoints, suggesting that the q4wks dosing regimen is more effective.
• The study involved 38 participants with Alzheimer's disease, aged 50 to 86, with Mini-Mental State Examination (MMSE) scores ranging from 12 to 26.
• The q4wks group showed a clinically meaningful 4.93-point improvement in the ADAS-Cog14 score compared to placebo, although this was not statistically significant (p=0.061).
• The study was funded by the Alzheimer's Association, the Gates Foundation, and the National Institute on Aging, with additional support from Coya.

Sentiment

Score: 8

Explanation: The document presents positive results from a Phase 2 trial, meeting primary and secondary endpoints, and showing promising trends in cognitive stabilization and biomarker improvements. The company is also planning future trials and combination strategies, indicating a positive outlook.

Positives

• The study demonstrated that LD IL-2 is safe and well-tolerated in patients with Alzheimer's disease.
• The LD IL-2 q4wks regimen showed a significant expansion of regulatory T cell populations without off-target effects.
• The q4wks regimen led to significant improvements in CSF-soluble A42 levels, an indicator of amyloid pathology.
• The q4wks regimen showed a promising trend in stabilizing cognitive function.
• The study provides further validation of Coya's approach in modulating Treg function as a platform to address neurodegenerative diseases.
• The results increase confidence in the potential of COYA 302, a combination therapy, for treating ALS and FTD.

Negatives

• The LD IL-2 q2wks group did not exhibit benefits in exploratory endpoints, suggesting that higher dosing may compromise Treg functionality.
• The cognitive improvement in the q4wks group was not statistically significant (p=0.061).
• The study was not powered for statistical significance in the exploratory endpoints.

Risks

• The cognitive improvement observed in the study was not statistically significant, which may impact future trial design and regulatory approval.
• The study was not powered for statistical significance in the exploratory endpoints, which may limit the conclusions that can be drawn.
• The q2wks dosing regimen showed a reduction in Foxp3 expression, a critical marker of Treg functionality, indicating that higher doses may not be beneficial.
• The company is still in the clinical stage and has not yet received regulatory approval for any of its products.
• The company's future success depends on the outcome of ongoing and planned clinical trials.

Future Outlook

Coya plans to advance the LD IL-2 q4wks regimen and explore combination strategies with COYA 301 in larger cohorts of Alzheimer's patients. They also plan clinical trials for COYA 302 in ALS and FTD.

Management Comments

• Arun Swaminathan, Ph.D., incoming CEO of Coya, stated that the trial strongly supports and adds further validation of Coya's approach in modulating Treg function.
• Management believes that the monotherapy treatment results increase their confidence that combinations of COYA 301 with other drug targets have strong potential in treating Alzheimer's Disease.
• Management believes that the data on LD IL-2 alone provides additional confidence in COYA 302 for ALS and FTD.

Industry Context

The announcement is significant as it provides further evidence for the potential of Treg modulation in treating neurodegenerative diseases, a growing area of research. The results also position Coya as a key player in the development of novel therapies for Alzheimer's disease, which currently has limited treatment options.

Comparison to Industry Standards

• The study's use of ADAS-Cog14 and CSF biomarkers aligns with industry standards for assessing cognitive function and disease pathology in Alzheimer's trials.
• The observed 4.93-point improvement in ADAS-Cog14 in the LD IL-2 q4wks group is clinically meaningful, as a change of +3 is considered significant for assessing worsening in mild AD, as per Muir et al., Alzheimers Dement 2024; 20:33523363.
• The study's focus on Treg modulation is a novel approach compared to traditional amyloid-targeting therapies, such as those developed by Biogen and Eisai (Aduhelm and Leqembi), which have shown modest clinical benefits and significant side effects.
• The use of low-dose IL-2 to enhance Treg function is a unique strategy compared to other immunotherapies in development for neurodegenerative diseases, such as those targeting microglia or other inflammatory pathways.
• The study's findings on CSF A42 levels are consistent with other studies showing that increased A42 levels are associated with slowing cognitive impairment, which is a key target for Alzheimer's therapies.

Stakeholder Impact

• Shareholders may view the positive trial results as a positive development, potentially increasing the company's stock value.
• Patients with Alzheimer's disease and their families may see the results as a promising step towards new treatment options.
• The scientific community may be interested in the study's findings on Treg modulation and its potential for treating neurodegenerative diseases.
• Employees of Coya may be motivated by the positive results and the company's progress in developing new therapies.

Next Steps

• Reporting of additional data from the LD IL-2 study documenting the effect of LD IL-2 treatment vs. placebo on systemic and CNS inflammatory markers.
• Discussions ongoing to advance other combination strategies with COYA 301 in larger cohorts of Alzheimer's Disease patients.
• Planned clinical trials for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD).

Key Dates

Keywords

Alzheimer's Disease, Low-Dose Interleukin-2, LD IL-2, Regulatory T cells, Tregs, Neurodegenerative Diseases, Clinical Trial, COYA 301, COYA 302, Amyloid Pathology, Cognitive Function, Cerebrospinal Fluid, CSF, Biomarkers